Trial reportJournal of gynecologic oncology2017
Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update.
Trial report in Journal of gynecologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Survival outcomes in IIIC cervical cancer by treatment strategies: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- The role of radiomics for predicting of lymph-vascular space invasion in cervical cancer patients based on artificial intelligence: a systematic review and meta-analysis.Journal of gynecologic oncology · 2025Pooled it
- Neoadjuvant and Adjuvant Treatments Compared to Concurrent Chemoradiotherapy for Patients With Locally Advanced Cervical Cancer: A Bayesian Network Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Indocyanine green versus technetium-99m with blue dye for sentinel lymph node detection in early-stage cervical cancer: A systematic review and meta-analysis.Cancer reports (Hoboken, N.J.) · 2022Pooled it
- Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis.Frontiers in oncology · 2022Pooled it
- Effectiveness comparisons of various therapies for FIGO stage IB2/IIA2 cervical cancer: a Bayesian network meta-analysis.BMC cancer · 2021Pooled it
- Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.The Cochrane database of systematic reviews · 2013Pooled it
- Using deep learning to predict survival outcome in non-surgical cervical cancer patients based on pathological images.Journal of cancer research and clinical oncology · 2023Trial
- Prediction of Postoperative Pathologic Risk Factors in Cervical Cancer Patients Treated with Radical Hysterectomy by Machine Learning.Current oncology (Toronto, Ont.) · 2022Trial
- Trial
- The Choice Between Definitive Radiotherapy and Surgery for Cervical Cancer With Different Histology in Current Clinical Practice.The Kaohsiung journal of medical sciences · 2026Article
- Characterizing trimodal therapy outcomes by HIV status in early-stage cervical cancer: a retrospective cohort study from a Kenyan tertiary centre.BMC cancer · 2026Article
- Gynecologic radiation oncology practice: retrospective analysis of a tertiary radiotherapy referral center.Frontiers in oncology · 2026Article
- Is Moderately Hypofractionated Radiotherapy a Safe and Effective Strategy for Cervical Cancer?-A Review of Current Evidence.Current oncology (Toronto, Ont.) · 2026Review
- The Evolving Role of Radiation Oncology in the Management of Uterine Cervical Carcinoma: A State-of-the-Art Review for Non-Radiation Oncologists.Life (Basel, Switzerland) · 2025Review
- Trends in radiotherapy use and implementation challenges among patients with cervical cancer: a multicenter study in Osaka, Japan.Journal of radiation research · 2025Article
- Cancer of the cervix uteri: 2025 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025Article
- Neoadjuvant chemoradiation and surgical excision versus definitive radiotherapy for locally advanced cervix uteri carcinoma: in terms of early and late complications and locoregional recurrence.Journal of the Egyptian National Cancer Institute · 2025Article
- Oncologic and obstetric outcomes of a novel nerve-sparing radical trachelectomy while preserving the uterine branches of the pelvic nerves.Translational cancer research · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStage IB-IIA cervical carcinoma can be equally cured either by radical surgery or radiotherapy (RT). Albeit such policies show the same efficacy, they carry a different morbidity. This is an update after 20 years of a previously published randomized trial of RT vs. surgery in the treatment of stage IB-IIA cervical cancers to assess long-term survival and morbidity and the different pattern of relapse between the 2 modalities.
methodsBetween September 1986 and December 1991, women referred for a newly diagnosed stage IB and IIA cervical carcinoma were randomized to radical surgery or RT. The primary outcome measures were long-term survival and complications rate. The secondary outcome was recurrence of the disease.
resultsThree-hundred forty-three eligible women were randomized: 172 to radical surgery and 171 to external RT. Minimum follow-up was 19 years. Thirty-three patients (10%) died of intercurrent disease (31 cases) or fatal complications (2 cases). Twenty-year overall survival is 72% and 77% in the 2 treatment groups (p=0.280), respectively. As a whole, 94 recurrences (28%) were observed. Median time to relapse was 13.5 (surgery group) and 11.5 months (radiotherapy group) (p=0.100), respectively. Multivariate analysis confirms that risk factors for survival are histotype (p=0.020), tumor diameter (p=0.008), and lymph node status (p<0.001).
conclusionThe results of the present study seem to suggest that there is no treatment of choice for early stage cervical carcinoma in terms of survival. Long term follow-up confirms that the best treatment for the individual patient should take into account clinical factors such as menopausal status, comorbidities, histological type, and tumor diameter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.